Abe Bassan is a Vice President at Samsara BioCapital. He was previously Director of Program Biology at Revolution Medicines, where he co-led the initial stages of the company’s 4EBP1/mTORC1 cancer program. Prior to that, Abe was at bluebird bio, where he was the project manager for the company’s β-Thalassemia, Sickle Cell Anemia, and ALD gene therapy programs. Before bluebird, Abe was an Associate at Third Rock Ventures, where he was involved in the firm’s investment in bluebird bio and concept creation for Blueprint Medicines, a precision medicine oncology company. Abe was also the founder of Aurora Medical, a molecular diagnostics testing services company. Abe received an A.B. in Molecular Biology from Princeton University, and an M.S. in Developmental Biology from Stanford University.